LXS-196

• Description:

  LXS-196 is an orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, LXS-196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells.

• Shipping Conditions:

  gel pack

• Storage Conditions:

  -20°C

• Shelf Life:

  36 months